Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Turn Therapeutics Inc ( (TTRX) ) has shared an update.
On November 4, 2025, Turn Therapeutics announced the appointment of Andrew Scott as Vice President of Corporate Communications. This strategic hire comes as the company, following its public listing, aims to enhance investor relations and expand its market presence, with Scott’s extensive experience expected to guide the company through upcoming milestones, including the completion of its Phase 2 clinical program.
More about Turn Therapeutics Inc
Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious disease. The company has received FDA clearances for its proprietary formulations and is advancing clinical programs in eczema and onychomycosis, while also pursuing global health initiatives in vaccine delivery.
Average Trading Volume: 1,284,296
See more data about TTRX stock on TipRanks’ Stock Analysis page.